1
|
McNamara N, Rahmani R, Sykes ML, Avery VM, Baell J. Hit-to-lead optimization of novel benzimidazole phenylacetamides as broad spectrum trypanosomacides. RSC Med Chem 2020; 11:685-695. [PMID: 33479668 DOI: 10.1039/d0md00058b] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Accepted: 05/12/2020] [Indexed: 12/21/2022] Open
Abstract
Trypanosoma cruzi and Trypanosoma brucei are the parasitic causative agents of Chagas disease and human African trypanosomiasis (HAT), respectively. The drugs currently used to treat these diseases are not efficacious against all stages and/or parasite sub-species, often displaying side effects. Herein, we report the SAR exploration of a novel hit, 2-(4-chlorophenyl)-N-(1-propyl-1H-benzimidazol-2-yl)acetamide previously identified from high throughput screens against T. cruzi, Trypanosoma brucei brucei and Leishmania donovani. An informative set of analogues was synthesized incorporating key modifications of the scaffold resulting in improved potency whilst the majority of compounds retained low cytotoxicity against H9c2 and HEK293 cell lines. The SAR observed against T. cruzi broadly matches that observed against T.b. brucei, suggesting the possibility for a broad-spectrum candidate. This class of compounds therefore warrants further investigation towards development as a treatment for Chagas disease and HAT.
Collapse
Affiliation(s)
- Nicole McNamara
- Medicinal Chemistry , Monash Institute of Pharmaceutical Sciences , Monash University , Parkville , Victoria 3052 , Australia .
| | - Raphael Rahmani
- Medicinal Chemistry , Monash Institute of Pharmaceutical Sciences , Monash University , Parkville , Victoria 3052 , Australia .
| | - Melissa L Sykes
- Discovery Biology , Griffith Institute for Drug Discovery , Griffith University , Brisbane Innovation Park, Don Young Road , Nathan , Queensland 4111 , Australia
| | - Vicky M Avery
- Discovery Biology , Griffith Institute for Drug Discovery , Griffith University , Brisbane Innovation Park, Don Young Road , Nathan , Queensland 4111 , Australia
| | - Jonathan Baell
- Medicinal Chemistry , Monash Institute of Pharmaceutical Sciences , Monash University , Parkville , Victoria 3052 , Australia .
| |
Collapse
|
2
|
Wang L, Zhang Y, Du X, Ding T, Gong W, Liu F. Review of antidepressants in clinic and active ingredients of traditional Chinese medicine targeting 5-HT1A receptors. Biomed Pharmacother 2019; 120:109408. [DOI: 10.1016/j.biopha.2019.109408] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Revised: 08/26/2019] [Accepted: 08/28/2019] [Indexed: 12/13/2022] Open
|
3
|
An insight into the medicinal perspective of synthetic analogs of indole: A review. Eur J Med Chem 2019; 180:562-612. [PMID: 31344615 DOI: 10.1016/j.ejmech.2019.07.019] [Citation(s) in RCA: 170] [Impact Index Per Article: 34.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 06/23/2019] [Accepted: 07/06/2019] [Indexed: 01/06/2023]
Abstract
Heterocycles occupy a salient place in chemistry due to their wide range of activity in the fields of drug design, photochemistry, agrochemicals, dyes, and so on. Amongst all, indole scaffold is considered as one of the most promising heterocycles found in natural and synthetic sources and has been shown to possess various biological activity, including anti-inflammatory, anti-HIV, antitubercular, antimalarial, anticonvulsant, antidiabetic, antihypertensive, analgesics, antidepressant, anticancer, antioxidant, antifungal, and antimicrobial, etc. All the reported indole molecules bind to multiple receptors with high affinity, thus expedite the research on the development of novel biologically active compounds through the various approach. In this review, we aimed to highlight synthetic and medicinal perspective on the development of indole-based analogs. In addition, structural activity relationship (SAR) study to correlate for their biological activity also discussed.
Collapse
|
4
|
Tjin CC, Wissner RF, Jamali H, Schepartz A, Ellman JA. Synthesis and Biological Evaluation of an Indazole-Based Selective Protein Arginine Deiminase 4 (PAD4) Inhibitor. ACS Med Chem Lett 2018; 9:1013-1018. [PMID: 30344909 DOI: 10.1021/acsmedchemlett.8b00283] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Accepted: 09/14/2018] [Indexed: 12/22/2022] Open
Abstract
Protein arginine deiminase 4 (PAD4) is a calcium-dependent enzyme that catalyzes the conversion of arginine to citrulline within target proteins. Dysregulation of PAD4 has been implicated in a number of human diseases, including rheumatoid arthritis and other inflammatory diseases as well as cancer. In this study, we report on the design, synthesis, and evaluation of a new class of haloacetamidine-based compounds as potential PAD4 inhibitors. Specifically, we describe the identification of 4,5,6-trichloroindazole 24 as a highly potent PAD4 inhibitor that displays >10-fold selectivity for PAD4 over PAD3 and >50-fold over PAD1 and PAD2. The efficacy of this compound in cells was determined by measuring the inhibition of PAD4-mediated H4 citrullination in HL-60 granulocytes.
Collapse
|
5
|
Gu ZS, Zhou AN, Xiao Y, Zhang QW, Li JQ. Synthesis and antidepressant-like activity of novel aralkyl piperazine derivatives targeting SSRI/5-HT 1A /5-HT 7. Eur J Med Chem 2018; 144:701-715. [DOI: 10.1016/j.ejmech.2017.12.063] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Revised: 12/16/2017] [Accepted: 12/16/2017] [Indexed: 12/24/2022]
|
6
|
Männel B, Dengler D, Shonberg J, Hübner H, Möller D, Gmeiner P. Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D2R Agonists. J Med Chem 2017; 60:4693-4713. [DOI: 10.1021/acs.jmedchem.7b00363] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Barbara Männel
- Department of Chemistry and
Pharmacy, Medicinal Chemistry, Friedrich-Alexander University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany
| | - Daniela Dengler
- Department of Chemistry and
Pharmacy, Medicinal Chemistry, Friedrich-Alexander University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany
| | - Jeremy Shonberg
- Department of Chemistry and
Pharmacy, Medicinal Chemistry, Friedrich-Alexander University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany
| | - Harald Hübner
- Department of Chemistry and
Pharmacy, Medicinal Chemistry, Friedrich-Alexander University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany
| | - Dorothee Möller
- Department of Chemistry and
Pharmacy, Medicinal Chemistry, Friedrich-Alexander University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany
| | - Peter Gmeiner
- Department of Chemistry and
Pharmacy, Medicinal Chemistry, Friedrich-Alexander University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany
| |
Collapse
|
7
|
Milelli A, Turrini E, Catanzaro E, Maffei F, Fimognari C. Perspectives in Designing Multifunctional Molecules in Antipsychotic Drug Discovery. Drug Dev Res 2016; 77:437-443. [DOI: 10.1002/ddr.21334] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2016] [Accepted: 08/02/2016] [Indexed: 11/09/2022]
Affiliation(s)
- Andrea Milelli
- Department for Life Quality Studies; Alma Mater Studiorum - University of Bologna, C.so d'Augusto 237; Rimini 47921 Italy
| | - Eleonora Turrini
- Department for Life Quality Studies; Alma Mater Studiorum - University of Bologna, C.so d'Augusto 237; Rimini 47921 Italy
| | - Elena Catanzaro
- Department for Life Quality Studies; Alma Mater Studiorum - University of Bologna, C.so d'Augusto 237; Rimini 47921 Italy
| | - Francesca Maffei
- Department for Life Quality Studies; Alma Mater Studiorum - University of Bologna, C.so d'Augusto 237; Rimini 47921 Italy
| | - Carmela Fimognari
- Department for Life Quality Studies; Alma Mater Studiorum - University of Bologna, C.so d'Augusto 237; Rimini 47921 Italy
| |
Collapse
|
8
|
Nenkep V, Yun K, Son BW. Oxysporizoline, an antibacterial polycyclic quinazoline alkaloid from the marine-mudflat-derived fungus Fusarium oxysporum. J Antibiot (Tokyo) 2016; 69:709-11. [PMID: 26732255 DOI: 10.1038/ja.2015.137] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Revised: 10/20/2015] [Accepted: 11/12/2015] [Indexed: 11/09/2022]
Affiliation(s)
- Viviane Nenkep
- Department of Chemistry, Pukyong National University, Busan, Korea
| | - Keumja Yun
- Department of Chemistry, Pukyong National University, Busan, Korea
| | - Byeng Wha Son
- Department of Chemistry, Pukyong National University, Busan, Korea
| |
Collapse
|
9
|
Sun N, Huang P, Wang Y, Mo W, Hu B, Shen Z, Hu X. Zeolite-catalyzed synthesis of 2,3-unsubstituted benzo[b]furans via the intramolecular cyclization of 2-aryloxyacetaldehyde acetals. Tetrahedron 2015. [DOI: 10.1016/j.tet.2015.05.029] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
10
|
Kruegel AC, Rakshit S, Li X, Sames D. Constructing Iboga alkaloids via C-H bond functionalization: examination of the direct and catalytic union of heteroarenes and isoquinuclidine alkenes. J Org Chem 2015; 80:2062-71. [PMID: 25633249 DOI: 10.1021/jo5018102] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The iboga alkaloids have attracted considerable attention in both the scientific community and popular media due to their reported ability to reverse or markedly diminish cravings for, and self-administration of, the major drugs of abuse. We have developed three new intramolecular C-H functionalization procedures leading to the core seven-membered ring of the iboga skeleton, a cyclization that proved to be highly challenging. The electrophilic palladium salt Pd(CH3CN)4(BF4)2 was effective for the cyclization of diverse N-(2-arylethyl)isoquinuclidines with yields of 10-35%. A two-step, bromination-reductive Heck reaction protocol was also effective for the synthesis of ibogamine in 42% yield. Finally, a direct Ni(0)-catalyzed C-H functionalization provided the benzofuran analogues of ibogamine (74%) and epi-ibogamine (38%). Although each approach suffers from significant shortcomings, in combination, the methods described provide practical routes to diverse ibogamine analogues.
Collapse
Affiliation(s)
- Andrew C Kruegel
- Department of Chemistry, Columbia University , New York, New York 10027, United States
| | | | | | | |
Collapse
|
11
|
Ojeda-Gómez C, Pessoa-Mahana H, Iturriaga-Vásquez P, Pessoa-Mahana CD, Recabarren-Gajardo G, Méndez-Rojas C. Synthesis and biological screening of novel indolalkyl arenes targeting the serotonine transporter. Arch Pharm (Weinheim) 2013; 347:174-84. [PMID: 24339227 DOI: 10.1002/ardp.201300321] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2013] [Revised: 09/30/2013] [Accepted: 10/01/2013] [Indexed: 11/05/2022]
Abstract
A series of functionalized indolylalkylarenes 3-16(a and b) were synthesized and their affinities for the serotonin transporter were investigated in vitro. Compounds 3-12(a and b) were obtained by nucleophilic substitution of 3-(1H-indol-3-yl)propyl-4-methylbenzenesulfonates 2(a and b) with a series of azaheterocycles. Compounds 14-16(a and b) were prepared in a two-step sequence by reaction of 3-(1H-indol-3-yl)-2-methylpropanal with substituted 1,2-phenylenediamines. Compounds 3b, 4b, and 5b showed good binding affinities (K(i) = 33.0, 48.0, and 17 nM, respectively). The other synthesized compounds showed moderate or no affinity in the binding studies.
Collapse
Affiliation(s)
- Claudia Ojeda-Gómez
- Faculty of Chemical and Pharmaceutical Sciences, Department of Organic and Physical Chemistry, University of Chile, Santiago, Chile
| | | | | | | | | | | |
Collapse
|
12
|
Wang S, Chen Y, Liu X, Xu X, Liu X, Liu BF, Zhang G. Synthesis and evaluation of novel 2,3-dihydrobenzo[b][1,4]dioxin- and indolealkylamine derivatives as potential antidepressants. Arch Pharm (Weinheim) 2013; 347:32-41. [PMID: 24214603 DOI: 10.1002/ardp.201300238] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2013] [Revised: 09/01/2013] [Accepted: 09/05/2013] [Indexed: 11/06/2022]
Abstract
A series of 2,3-dihydrobenzo[b][1,4]dioxin- and indolealkylamine derivatives were synthesized and the target compounds were evaluated for their binding affinities at the 5-HT1A receptor and serotonin transporter. Antidepressant-like activities of the compounds were screened using the tail suspension and forced swim tests in mice. Preliminary results indicated that the target compounds exhibited high binding affinities at the 5-HT1A receptor and serotonin transporter, and produced marked antidepressant-like effects. The best example from this study, compound 5, exhibited high binding affinities for the 5-HT1A receptor (Ki = 96 nM) and serotonin transporter (Ki = 9.8 nM). The intrinsic activity of compound 5 showed agonistic property to the 5-HT1A receptor and inhibition of the 5-HT transporter. Furthermore, compound 5 exhibited greater antidepressant efficacy than fluoxetine and showed acceptable pharmacokinetic properties.
Collapse
Affiliation(s)
- Songlin Wang
- Department of Biomedical Engineering, Systems Biology Theme, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China
| | | | | | | | | | | | | |
Collapse
|
13
|
Soubhye J, Aldib I, Elfving B, Gelbcke M, Furtmüller PG, Podrecca M, Conotte R, Colet JM, Rousseau A, Reye F, Sarakbi A, Vanhaeverbeek M, Kauffmann JM, Obinger C, Nève J, Prévost M, Zouaoui Boudjeltia K, Dufrasne F, Van Antwerpen P. Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors. J Med Chem 2013; 56:3943-58. [PMID: 23581551 DOI: 10.1021/jm4001538] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Due to its production of potent antimicrobial oxidants including hypochlorous acid, human myeloperoxidase (MPO) plays a critical role in innate immunity and inflammatory diseases. Thus MPO is an attractive target in drug design. (Aminoalkyl)fluoroindole derivatives were detected to be very potent MPO inhibitors; however, they also promote inhibition of the serotonin reuptake transporter (SERT) at the same concentration range. Via structure-based drug design, a new series of MPO inhibitors derived from 3-alkylindole were synthesized and their effects were assessed on MPO-mediated taurine chlorination and low-density lipoprotein oxidation as well as on inhibition of SERT. The fluoroindole compound with three carbons in the side chain and one amide group exhibited a selectivity index of 35 (Ki/IC50) with high inhibition of MPO activity (IC50 = 18 nM), whereas its effect on SERT was in the micromolar range. Structure-function relationships, mechanism of action, and safety of the molecule are discussed.
Collapse
Affiliation(s)
- Jalal Soubhye
- Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles, 1050 Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Lacivita E, Di Pilato P, De Giorgio P, Colabufo NA, Berardi F, Perrone R, Leopoldo M. The therapeutic potential of 5-HT1A receptors: a patent review. Expert Opin Ther Pat 2012; 22:887-902. [DOI: 10.1517/13543776.2012.703654] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
15
|
Gigant N, Claveau E, Bouyssou P, Gillaizeau I. Diversity-oriented synthesis of polycyclic diazinic scaffolds. Org Lett 2012; 14:844-7. [PMID: 22260530 DOI: 10.1021/ol203364b] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
An efficient and versatile synthesis of a polycyclic diazinic system starting from oxazine has been developed using a two-step Michael/retro Michael and cyclization sequence. The substrates were synthesized with good to high yields giving rapid access to molecular diversity.
Collapse
Affiliation(s)
- Nicolas Gigant
- Institut de Chimie Organique et Analytique, UMR 7311 CNRS, rue de Chartres, Université d'Orléans, F-45067 Orléans Cedex 2, France
| | | | | | | |
Collapse
|
16
|
Wang L, Ma C, Wipf P, Xie XQ. Linear and Nonlinear Support Vector Machine for the Classification of Human 5-HT1A Ligand Functionality. Mol Inform 2012; 31:85-95. [PMID: 27478180 DOI: 10.1002/minf.201100126] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2011] [Accepted: 12/11/2011] [Indexed: 11/06/2022]
Abstract
Upon binding to a receptor, agonists and antagonists can induce distinct biological functions and thus lead to significantly different pharmacological responses. Thus, in silico prediction or in vitro characterization of ligand agonistic or antagonistic functionalities is an important step toward identifying specific pharmacological therapeutics. In this study, we investigated the molecular properties of agonists and antagonists of human 5-hydroxytryptamine receptor subtype 1A (5-HT1A ). Subsequently, intrinsic functions of these ligands (agonists/antagonists) were modeled by support vector machine (SVM), using five 2D molecular fingerprints and the 3D Topomer distance. Five kernel functions, including linear, polynomial, RBF, Tanimoto and a novel Topomer kernel based on Topomer 3D similarity were used to develop linear and nonlinear classifiers. These classifiers were validated through cross-validation, yielding a classification accuracy ranging from 80.4 % to 92.3 %. The performance of different kernels and fingerprints was analyzed and discussed. Linear and nonlinear models were further interpreted through the illustration of underlying classification mechanism. The computation protocol has been automated and demonstrated through our online service. This study expands the scope and applicability of similarity-based methods in cheminformatics, which are typically used for the identification of active molecules against a target protein. Our findings provide a good starting point for further systematic classifications of other GPCR ligands and for the data mining of large chemical libraries.
Collapse
Affiliation(s)
- Lirong Wang
- Department of Pharmaceutical Sciences, School of Pharmacy, Center for Chemical Methodologies & Library Development (UP-CMLD), Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA tel.: +1-412-383-5276; fax: +1-412-383-7436
| | - Chao Ma
- Department of Pharmaceutical Sciences, School of Pharmacy, Center for Chemical Methodologies & Library Development (UP-CMLD), Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA tel.: +1-412-383-5276; fax: +1-412-383-7436.,Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Peter Wipf
- Department of Pharmaceutical Sciences, School of Pharmacy, Center for Chemical Methodologies & Library Development (UP-CMLD), Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA tel.: +1-412-383-5276; fax: +1-412-383-7436.,Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Xiang-Qun Xie
- Department of Pharmaceutical Sciences, School of Pharmacy, Center for Chemical Methodologies & Library Development (UP-CMLD), Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA tel.: +1-412-383-5276; fax: +1-412-383-7436. .,Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA.
| |
Collapse
|
17
|
Martin DBC, Nguyen LQ, Vanderwal CD. Syntheses of Strychnine, Norfluorocurarine, Dehydrodesacetylretuline, and Valparicine Enabled by Intramolecular Cycloadditions of Zincke Aldehydes. J Org Chem 2011; 77:17-46. [DOI: 10.1021/jo2020246] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- David B. C. Martin
- 1102 Natural Sciences II, Department of Chemistry, University of California, Irvine, California, 92697-2025
| | - Lucas Q. Nguyen
- 1102 Natural Sciences II, Department of Chemistry, University of California, Irvine, California, 92697-2025
| | - Christopher D. Vanderwal
- 1102 Natural Sciences II, Department of Chemistry, University of California, Irvine, California, 92697-2025
| |
Collapse
|
18
|
Soubhye J, Prévost M, Van Antwerpen P, Zouaoui Boudjeltia K, Rousseau A, Furtmüller PG, Obinger C, Vanhaeverbeek M, Ducobu J, Nève J, Gelbcke M, Dufrasne F. Structure-Based Design, Synthesis, and Pharmacological Evaluation of 3-(Aminoalkyl)-5-fluoroindoles as Myeloperoxidase Inhibitors. J Med Chem 2010; 53:8747-59. [DOI: 10.1021/jm1009988] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jalal Soubhye
- Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Martine Prévost
- Laboratoire de Structure et Fonction des Membranes Biologiques, Université Libre de Bruxelles, Brussels, Belgium
| | - Pierre Van Antwerpen
- Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
- Analytical Platform of the Faculty of Pharmacy, Université Libre de Bruxelles, Brussels, Belgium
| | - Karim Zouaoui Boudjeltia
- Laboratory of Experimental Medicine, CHU Charleroi, A. Vésale Hospital, Université Libre de Bruxelles, Montigny-le-Tilleul, Belgium
| | - Alexandre Rousseau
- Laboratory of Experimental Medicine, CHU Charleroi, A. Vésale Hospital, Université Libre de Bruxelles, Montigny-le-Tilleul, Belgium
| | - Paul G. Furtmüller
- Department of Chemistry, Division of Biochemistry, BOKU—University of Natural Resources and Life Sciences, Vienna, Austria
| | - Christian Obinger
- Department of Chemistry, Division of Biochemistry, BOKU—University of Natural Resources and Life Sciences, Vienna, Austria
| | - Michel Vanhaeverbeek
- Laboratory of Experimental Medicine, CHU Charleroi, A. Vésale Hospital, Université Libre de Bruxelles, Montigny-le-Tilleul, Belgium
| | - Jean Ducobu
- Laboratory of Experimental Medicine, CHU Charleroi, A. Vésale Hospital, Université Libre de Bruxelles, Montigny-le-Tilleul, Belgium
| | - Jean Nève
- Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Michel Gelbcke
- Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Franc¸ois Dufrasne
- Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
19
|
Leslie CP, Biagetti M, Bison S, Bromidge SM, Di Fabio R, Donati D, Falchi A, Garnier MJ, Jaxa-Chamiec A, Manchee G, Merlo G, Pizzi DA, Stasi LP, Tibasco J, Vong A, Ward SE, Zonzini L. Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, Selective, and Orally Active 5-HT1A/B/D Receptor Antagonist. J Med Chem 2010; 53:8228-40. [DOI: 10.1021/jm100714c] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Colin P. Leslie
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Matteo Biagetti
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Silvia Bison
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Steven M. Bromidge
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom
| | - Romano Di Fabio
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Daniele Donati
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Alessandro Falchi
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Martine J. Garnier
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Albert Jaxa-Chamiec
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Gary Manchee
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Giancarlo Merlo
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Domenica A. Pizzi
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Luigi P. Stasi
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Jessica Tibasco
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Antonio Vong
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom
| | - Simon E. Ward
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom
| | - Laura Zonzini
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| |
Collapse
|
20
|
Yeung BKS, Zou B, Rottmann M, Lakshminarayana SB, Ang SH, Leong SY, Tan J, Wong J, Keller-Maerki S, Fischli C, Goh A, Schmitt EK, Krastel P, Francotte E, Kuhen K, Plouffe D, Henson K, Wagner T, Winzeler EA, Petersen F, Brun R, Dartois V, Diagana TT, Keller TH. Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem 2010; 53:5155-64. [PMID: 20568778 PMCID: PMC6996867 DOI: 10.1021/jm100410f] [Citation(s) in RCA: 318] [Impact Index Per Article: 22.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
![]()
The antiplasmodial activity of a series of spirotetrahydro β-carbolines is described. Racemic spiroazepineindole (1) was identified from a phenotypic screen on wild type Plasmodium falciparum with an in vitro IC50 of 90 nM. Structure−activity relationships for the optimization of 1 to compound 20a (IC50 = 0.2 nM) including the identification of the active 1R,3S enantiomer and elimination of metabolic liabilities is presented. Improvement of the pharmacokinetic profile of the series translated to exceptional oral efficacy in the P. berghei infected malaria mouse model where full cure was achieved in four of five mice with three daily doses of 30 mg/kg.
Collapse
Affiliation(s)
- Bryan K S Yeung
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01 Chromos, Singapore 138670.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Venkatesan AM, Dos Santos O, Ellingboe J, Evrard DA, Harrison BL, Smith DL, Scerni R, Hornby GA, Schechter LE, Andree TH. Novel benzofuran derivatives with dual 5-HT1A receptor and serotonin transporter affinity. Bioorg Med Chem Lett 2010; 20:824-7. [PMID: 20064720 DOI: 10.1016/j.bmcl.2009.12.093] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2009] [Revised: 12/21/2009] [Accepted: 12/24/2009] [Indexed: 11/25/2022]
|
22
|
Chiummiento L, Funicello M, Lupattelli P, Tramutola F, Campaner P. New indolic non-peptidic HIV protease inhibitors from (S)-glycidol: synthesis and preliminary biological activity. Tetrahedron 2009. [DOI: 10.1016/j.tet.2009.05.089] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Beyer CE, Lin Q, Platt B, Malberg J, Hornby G, Sullivan KM, Smith DL, Lock T, Mitchell PJ, Hatzenbuhler NT, Evrard DA, Harrison BL, Magolda R, Pangalos MN, Schechter LE, Rosenzweig-Lipson S, Andree TH. Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant. Br J Pharmacol 2009; 157:307-19. [PMID: 19338583 DOI: 10.1111/j.1476-5381.2009.00146.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND AND PURPOSE As a combination of 5-HT selective reuptake inhibitor (SSRI) with 5-HT(1A) receptor antagonism may yield a rapidly acting antidepressant, WAY-211612, a compound with both SSRI and 5-HT(1A) receptor antagonist activities, was evaluated in preclinical models. EXPERIMENTAL APPROACH Occupancy studies confirmed the mechanism of action of WAY-211612, while its in vivo profile was characterized in microdialysis and behavioural models. KEY RESULTS WAY-211612 inhibited 5-HT reuptake (K(i) = 1.5 nmol.L(-1); K(B) = 17.7 nmol.L(-1)) and exhibited full 5-HT(1A) receptor antagonist activity (K(i) = 1.2 nmol.L(-1); K(B) = 6.3 nmol.L(-1); I(max) 100% in adenyl cyclase assays; K(B) = 19.8 nmol.L(-1); I(max) 100% in GTPgammaS). WAY-211612 (3 and 30 mg.kg(-1), po) occupied 5-HT reuptake sites in rat prefrontal cortex (56.6% and 73.6% respectively) and hippocampus (52.2% and 78.5%), and 5-HT(1A) receptors in the prefrontal cortex (6.7% and 44.7%), hippocampus (8.3% and 48.6%) and dorsal raphe (15% and 83%). Acute or chronic treatment with WAY-211612 (3-30 mg.kg(-1), po) raised levels of cortical 5-HT approximately twofold, as also observed with a combination of an SSRI (fluoxetine; 30 mg.kg(-1), s.c.) and a 5-HT(1A) antagonist (WAY-100635; 0.3 mg.kg(-1), s.c). WAY-211612 (3.3-30 mg.kg(-1), s.c.) decreased aggressive behaviour in the resident-intruder model, while increasing the number of punished crossings (3-30 mg.kg(-1), i.p. and 10-56 mg.kg(-1), po) in the mouse four-plate model and decreased adjunctive drinking behaviour (56 mg.kg(-1), i.p.) in the rat scheduled-induced polydipsia model. CONCLUSIONS AND IMPLICATIONS These findings suggest that WAY-211612 may represent a novel antidepressant.
Collapse
Affiliation(s)
- C E Beyer
- Discovery Neuroscience, Wyeth Research, Princeton, NJ 08543-8000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
New 3-(4-arylpiperazin-1-yl)-1-(benzo[b]thiophen-3-yl)-2-methylpropanol derivatives: Synthesis and evaluation for dual 5-HT1A/SSRI activities. CHINESE CHEM LETT 2008. [DOI: 10.1016/j.cclet.2008.01.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Wu XD, Liu DZ, Li AJ, Zhou XQ. Arylpiperazine derivatives of diphenylsulfide: Synthesis and evaluation for dual 5-HT1A/SSRI activities. CHINESE CHEM LETT 2008. [DOI: 10.1016/j.cclet.2008.01.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
26
|
Wu XD, Liu DZ, Li AJ, Zhou XQ. N-(2-(2-Methoxyphenylthio)benzyl)-2-aryloxyethylamines: Synthesis and evaluation for dual 5-HT1A/SSRI activities. CHINESE CHEM LETT 2008. [DOI: 10.1016/j.cclet.2008.01.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
|
28
|
1-(N-(2-(2-Methoxyphenylthio)benzyl)-N-methylamino-3-aryloxypropan-2-ols: Synthesis and evaluation for dual 5-HT1A/SSRI activities. CHINESE CHEM LETT 2008. [DOI: 10.1016/j.cclet.2007.11.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
29
|
Wang X, Liu DZ, Li AJ. 1-[2-(2-Methoxyphenylthio) benzyl]-4-arylpiperazines derivatives: Synthesis and evaluation for dual 5-HT1A/SSRI activities. CHINESE CHEM LETT 2008. [DOI: 10.1016/j.cclet.2007.10.054] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
30
|
Zhou D, Hatzenbuhler NT, Gross JL, Harrison BL, Evrard DA, Chlenov M, Golembieski J, Hornby G, Schechter LE, Smith DL, Andree TH, Stack GP. Novel pyridyl-fused 3-amino chroman derivatives with dual action at serotonin transporter and 5-HT1A receptor. Bioorg Med Chem Lett 2007; 17:3117-21. [PMID: 17407811 DOI: 10.1016/j.bmcl.2007.03.049] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2007] [Revised: 03/12/2007] [Accepted: 03/12/2007] [Indexed: 10/23/2022]
Abstract
Structural modifications of the initial lead, 3-aminochroman (4), led to the identification of a novel series of pyridyl-fused amino chroman derivatives (5-8) and the structural isomers (9-12). The compounds described were evaluated for dual 5-HT transporter inhibitory and 5-HT(1A) receptor activities. The design strategy, synthesis, and in vitro biological characterization for these novel compounds are described.
Collapse
Affiliation(s)
- Dahui Zhou
- Chemical and Screening Sciences, Wyeth Research, CN 8000, Princeton, NJ 08543-8000, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Adachi H, Palaniappan KK, Ivanov AA, Bergman N, Gao ZG, Jacobson KA. Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem 2007; 50:1810-27. [PMID: 17378544 PMCID: PMC3405160 DOI: 10.1021/jm061278q] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
2, N6, and 5'-substituted adenosine derivatives were synthesized via alkylation of 2-oxypurine nucleosides leading to 2-arylalkylether derivatives. 2-(3-(Indolyl)ethyloxy)adenosine 17 was examined in both binding and cAMP assays and found to be a potent agonist of the human A2BAR. Simplification, altered connectivity, and mimicking of the indole ring of 17 failed to maintain A2BAR potency. Introduction of N6-ethyl or N6-guanidino substitution, shown to favor A2BAR potency, failed to enhance potency in the 2-(3-(indolyl)ethyloxy)adenosine series. Indole 5' '- or 6' '-halo substitution was favored at the A2BAR, but a 5'-N-ethylcarboxyamide did not further enhance potency. 2-(3' '-(6' '-Bromoindolyl)ethyloxy)adenosine 28 displayed an A2BAR EC50 value of 128 nM, that is, more potent than the parent 17 (299 nM) and similar to 5'-N-ethylcarboxamidoadenosine (140 nM). Compound 28 was a full agonist at A2B and A2AARs and a low efficacy partial agonist at A1 and A3ARs. Thus, we have identified and optimized 2-(2-arylethyl)oxo moieties in AR agonists that enhance A2BAR potency and selectivity.
Collapse
Affiliation(s)
- Hayamitsu Adachi
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
| | - Krishnan K. Palaniappan
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
| | - Andrei A. Ivanov
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
| | - Nathaniel Bergman
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
| | - Zhan-Guo Gao
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
| | - Kenneth A. Jacobson
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
| |
Collapse
|
32
|
Yan S, Appleby T, Larson G, Wu JZ, Hamatake RK, Hong Z, Yao N. Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: Convergence of structure-based drug design and X-ray crystallographic study. Bioorg Med Chem Lett 2007; 17:1991-5. [PMID: 17276060 DOI: 10.1016/j.bmcl.2007.01.024] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2006] [Revised: 01/04/2007] [Accepted: 01/08/2007] [Indexed: 10/23/2022]
Abstract
A novel series of thiazolone-acylsulfonamides were designed as HCV NS5B polymerase allosteric inhibitors. The structure based drug designs (SBDD) were guided by docking results that revealed the potential to explore an additional pocket in the allosteric site. In particular, the designed molecules contain moieties of previously described thiazolone and a newly designed acylsulfonamide linker that is in turn connected with a substituted aromatic ring. The selected compounds were synthesized and demonstrated low muM activity. The X-ray complex structure was determined at a 2.2A resolution and converged with the SBDD principle.
Collapse
Affiliation(s)
- Shunqi Yan
- Valeant Pharmaceutical Research & Development, 3300 Hyland Ave., Costa Mesa, CA 92626, USA.
| | | | | | | | | | | | | |
Collapse
|
33
|
Cuisiat S, Bourdiol N, Lacharme V, Newman-Tancredi A, Colpaert F, Vacher B. Towards a New Generation of Potential Antipsychotic Agents Combining D2 and 5-HT1A Receptor Activities. J Med Chem 2007; 50:865-76. [PMID: 17300168 DOI: 10.1021/jm061180b] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We report the discovery and the synthesis of novel, potential antipsychotic compounds combining potent dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist properties in the same molecule. We describe the structure-activity relationship that lead us to the promising derivative: N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine 16. The latter has high affinity for D2 and 5-HT1A receptors, whereas it possesses only a weak affinity for 5-HT2A sites. In cellular models of signal transduction, 16 behaves as a silent antagonist at rD2 receptors while activating h5-HT1A receptors with an efficacy at least equivalent to that of the prototypical 5-HT1A agonist (+/-)-8-OH-DPAT. These dual actions confer a unique pharmacological profile to the product. In a behavioral model predictive of positive symptoms, 16 has an activity comparable to that of the typical antipsychotic haloperidol, while it is devoid of cataleptogenic effects. Although it produces behaviors characteristic of 5-HT1A receptor activation in rats, these occur at doses 100 times higher than those with (+/-)-8-OH-DPAT. We believe that the relative balance of D2 and 5-HT1A actions in 16 is appropriate, possibly optimal, to ensure superior efficacy and tolerability over existing antipychotic drugs.
Collapse
Affiliation(s)
- Stephane Cuisiat
- Pierre Fabre Research Center, 17 avenue Jean Moulin, 81106 Castres Cedex, France
| | | | | | | | | | | |
Collapse
|
34
|
Xie J, Seto CT. A two stage click-based library of protein tyrosine phosphatase inhibitors. Bioorg Med Chem 2006; 15:458-73. [PMID: 17046267 PMCID: PMC1764825 DOI: 10.1016/j.bmc.2006.09.036] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2006] [Revised: 09/18/2006] [Accepted: 09/20/2006] [Indexed: 01/20/2023]
Abstract
Protein tyrosine phosphatases (PTPs) are important regulators of signal transduction pathways. Potent and selective PTP inhibitors are useful for probing these pathways and also may serve as drugs for the treatment of a variety of diseases including type 2 diabetes and infection by the bacterium Yersinia pestis. In this report Cu(I)-catalyzed 'click' cycloaddition reactions between azides and alkynes were employed to generate two sequential libraries of PTP inhibitors. In the first round library methyl 4-azidobenzoylformate was reacted with 56 mono- and diynes. After hydrolysis of the methyl esters, the resulting alpha-ketocarboxylic acids were assayed in crude form against the Yersinia PTP and PTP1B. Four compounds were selected for further evaluation, and one compound was chosen as the lead for generation of the second round library. This lead compound was modified by conversion of an alcohol into an azide group, and the resulting azide was reacted with the same 56 mono- and diynes that were used in the first generation library. After screening the crude inhibitors against the Yersinia PTP and PTP1B, four compounds were selected and evaluated in pure form against the Yersinia PTP, PTP1B, TCPTP, LAR, and CD45. The best bis(alpha-ketocarboxylic acid) inhibitor 34 had an IC(50) value of 550nM against the Yersinia PTP and an IC(50) value of 710nM against TCPTP. The most potent inhibitor containing a single alpha-ketocarboxylic acid group 32 had IC(50) values of 2.1, 5.7, and 2.6 microM against the Yersinia PTP, PTP1B, and TCPTP, respectively.
Collapse
Affiliation(s)
| | - Christopher T. Seto
- *Department of Chemistry, Brown University, 324 Brook St. Box H, Providence, Rhode Island 02912, Phone: 401-863-3587; Fax: 401-863-9368,
| |
Collapse
|
35
|
Mowery BP, Prasad V, Kenesky CS, Angeles AR, Taylor LL, Feng JJ, Chen WL, Lin A, Cheng FC, Smith AB, Hirschmann R. Catechol: A Minimal Scaffold for Non-Peptide Peptidomimetics of thei+ 1 andi+ 2 Positions of the β-Turn of Somatostatin. Org Lett 2006; 8:4397-400. [PMID: 16986909 DOI: 10.1021/ol061488x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The design, synthesis, and evaluation of a series of catechol-based non-peptide peptidomimetics of the peptide hormone somatostatin have been achieved. These ligands comprise the simplest known non-peptide mimetics of the i + 1 and i + 2 positions of the somatostatin beta-turn. Incorporation of an additional side chain to include the i position of the beta-turn induces a selective 9-fold affinity enhancement at the sst2 receptor.
Collapse
Affiliation(s)
- Brendan P Mowery
- Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Hatzenbuhler NT, Evrard DA, Harrison BL, Huryn D, Inghrim J, Kraml C, Mattes JF, Mewshaw RE, Zhou D, Hornby G, Lin Q, Smith DL, Sullivan KM, Schechter LE, Beyer CE, Andree TH. Synthesis and biological evaluation of novel compounds within a class of 3-aminochroman derivatives with dual 5-HT1A receptor and serotonin transporter affinity. J Med Chem 2006; 49:4785-9. [PMID: 16854086 DOI: 10.1021/jm060218h] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Compounds containing a 5-carbamoyl-8-fluoro-3-amino-3,4-dihydro-2H-1-benzopyran and a 3-alkylindole moiety linked through a common basic nitrogen were prepared and evaluated for 5-HT1A affinity, serotonin rat transporter affinity, and functional antagonist activity in vitro. 26a was found to be the most potent and selective compound in this series and was shown to possess neurochemical activity in vivo by producing acute and rapid increases in 5-HT in the rat frontal cortex.
Collapse
Affiliation(s)
- Nicole T Hatzenbuhler
- Chemical and Screening Sciences and Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, New Jersey 08543, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110:135-370. [PMID: 16522330 DOI: 10.1016/j.pharmthera.2005.11.006] [Citation(s) in RCA: 388] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2005] [Accepted: 11/28/2005] [Indexed: 12/20/2022]
Abstract
Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a high social cost. Depressed patients generally display co-morbid symptoms, and depression frequently accompanies other serious disorders. Currently available drugs display limited efficacy and a pronounced delay to onset of action, and all provoke distressing side effects. Cloning of the human genome has fuelled expectations that symptomatic treatment may soon become more rapid and effective, and that depressive states may ultimately be "prevented" or "cured". In pursuing these objectives, in particular for genome-derived, non-monoaminergic targets, "specificity" of drug actions is often emphasized. That is, priority is afforded to agents that interact exclusively with a single site hypothesized as critically involved in the pathogenesis and/or control of depression. Certain highly selective drugs may prove effective, and they remain indispensable in the experimental (and clinical) evaluation of the significance of novel mechanisms. However, by analogy to other multifactorial disorders, "multi-target" agents may be better adapted to the improved treatment of depressive states. Support for this contention is garnered from a broad palette of observations, ranging from mechanisms of action of adjunctive drug combinations and electroconvulsive therapy to "network theory" analysis of the etiology and management of depressive states. The review also outlines opportunities to be exploited, and challenges to be addressed, in the discovery and characterization of drugs recognizing multiple targets. Finally, a diversity of multi-target strategies is proposed for the more efficacious and rapid control of core and co-morbid symptoms of depression, together with improved tolerance relative to currently available agents.
Collapse
Affiliation(s)
- Mark J Millan
- Institut de Recherches Servier, Centre de Recherches de Croissy, Psychopharmacology Department, 125, Chemin de Ronde, 78290-Croissy/Seine, France.
| |
Collapse
|
38
|
Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, Rosenzweig-Lipson S. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2006; 2:590-611. [PMID: 16489368 PMCID: PMC1201318 DOI: 10.1602/neurorx.2.4.590] [Citation(s) in RCA: 155] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Depression is a highly debilitating disorder that has been estimated to affect up to 21% of the world population. Despite the advances in the treatment of depression with selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), there continue to be many unmet clinical needs with respect to both efficacy and side effects. These needs range from efficacy in treatment resistant patients, to improved onset, to reductions in side effects such as emesis or sexual dysfunction. To address these needs, there are numerous combination therapies and novel targets that have been identified that may demonstrate improvements in one or more areas. There is tremendous diversity in the types of targets and approaches being taken. At one end of a spectrum is combination therapies that maintain the benefits associated with SSRIs but attempt to either improve efficacy or reduce side effects by adding additional mechanisms (5-HT1A, 5-HT1B, 5-HT1D, 5-HT2C, alpha-2A). At the other end of the spectrum are more novel targets, such as neurotrophins (BDNF, IGF), based on recent findings that antidepressants induce neurogenesis. In between, there are many approaches that range from directly targeting serotonin receptors (5-HT2C, 5-HT6) to targeting the multiplicity of potential mechanisms associated with excitatory (glutamate, NMDA, mGluR2, mGluR5) or inhibitory amino acid systems (GABA) or peptidergic systems (neurokinin 1, corticotropin-releasing factor 1, melanin-concentrating hormone 1, V1b). The present review addresses the most exciting approaches and reviews the localization, neurochemical and behavioral data that provide the supporting rationale for each of these targets or target combinations.
Collapse
Affiliation(s)
- Lee E Schechter
- Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, New Jersey 08543, USA.
| | | | | | | | | | | | | |
Collapse
|
39
|
Zhou D, Harrison BL, Shah U, Andree TH, Hornby GA, Scerni R, Schechter LE, Smith DL, Sullivan KM, Mewshaw RE. Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity. Bioorg Med Chem Lett 2006; 16:1338-41. [PMID: 16332439 DOI: 10.1016/j.bmcl.2005.11.054] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2005] [Revised: 11/11/2005] [Accepted: 11/14/2005] [Indexed: 11/30/2022]
Abstract
The design, synthesis, and structure-activity relationship of two novel classes of benzoxazine derivatives with dual selective serotonin reuptake inhibitors and 5-HT(1A) receptor activities are described.
Collapse
Affiliation(s)
- Dahui Zhou
- Chemical and Screening Sciences, Wyeth Research, CN 8000, Princeton, NJ 08543-8000, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
McCoy E, Galan MC, O'Connor SE. Substrate specificity of strictosidine synthase. Bioorg Med Chem Lett 2006; 16:2475-8. [PMID: 16481164 DOI: 10.1016/j.bmcl.2006.01.098] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2006] [Revised: 01/20/2006] [Accepted: 01/20/2006] [Indexed: 10/25/2022]
Abstract
Strictosidine synthase catalyzes a Pictet-Spengler reaction in the first step in the biosynthesis of terpene indole alkaloids to generate strictosidine. The substrate requirements for strictosidine synthase are systematically and quantitatively examined and the enzymatically generated compounds are processed by the second enzyme in this biosynthetic pathway.
Collapse
Affiliation(s)
- Elizabeth McCoy
- Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
| | | | | |
Collapse
|
41
|
Affiliation(s)
- Richard Morphy
- Medicinal Chemistry Department, Organon Laboratories, Newhouse, Lanarkshire, ML1 5SH, U.K.
| | | |
Collapse
|
42
|
Kling A, Lange UEW, Mack H, Bakker MHM, Drescher KU, Hornberger W, Hutchins CW, Möller A, Müller R, Schmidt M, Unger L, Wicke K, Schellhaas K, Steiner G. Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs. Bioorg Med Chem Lett 2005; 15:5567-73. [PMID: 16219465 DOI: 10.1016/j.bmcl.2005.04.077] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2005] [Revised: 04/25/2005] [Accepted: 04/28/2005] [Indexed: 11/26/2022]
Abstract
Novel 5-HT(1) autoreceptor ligands based on the N-4-aryl-piperazinyl-N'-ethyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one core are described. Aiming at antidepressants with a novel mode of action our objective was to identify potent antagonists showing balanced affinities and high selectivity for the 5-HT(1A) and 5-HT(1B) receptors. Strategies for the development of dual 5-HT(1A) and 5-HT(1B) antagonists based on 1 and 2 as leads and the corresponding results are discussed. Isoquinoline analogue 33 displayed high affinity and an antagonistic mode of action for the 5-HT(1A) and the 5-HT(1B) receptors and was characterized further with respect to selectivity, electrically stimulated [(3)H]5-HT release and in vivo efficacy.
Collapse
Affiliation(s)
- Andreas Kling
- Neuroscience Discovery, Abbott GmbH & Co. KG, D-67008 Ludwigshafen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Evrard DA, Zhou P, Yi SY, Zhou D, Smith DL, Sullivan KM, Hornby GA, Schechter LE, Andree TH, Mewshaw RE. Studies towards the next generation of antidepressants. Part 4: derivatives of 4-(5-fluoro-1H-indol-3-yl)cyclohexylamine with affinity for the serotonin transporter and the 5-HT1A receptor. Bioorg Med Chem Lett 2005; 15:911-4. [PMID: 15686885 DOI: 10.1016/j.bmcl.2004.12.064] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2004] [Revised: 12/17/2004] [Accepted: 12/21/2004] [Indexed: 11/30/2022]
Abstract
Derivatives of the serotonin reuptake inhibitor 4-(5-fluoro-1H-indol-3-yl)cyclohexylamine, in which serotonin 1A (5-HT(1A)) receptor pharmacophoric elements are incorporated, are reported. Analogs exhibiting affinity for both the serotonin transporter and the 5-HT(1A) receptor are described. Compounds containing 1-(4-indolyl)piperazine and 2-(1H-indol-4-yloxy)ethylamine are promising leads for further SAR studies.
Collapse
Affiliation(s)
- Deborah A Evrard
- Chemical and Screening Sciences, Wyeth Research, CN 8000, Princeton, NJ 08543, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Gilbert AM, Coleman T, Kodah J, Mewshaw RE, Scerni R, Schechter LE, Smith DL, Andree TH. Novel aryloxy-8-azabicyclo[3.2.1]oct-3-enes with 5-HT transporter and 5-HT1A affinity. Bioorg Med Chem Lett 2005; 14:5281-4. [PMID: 15454211 DOI: 10.1016/j.bmcl.2004.08.030] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2004] [Revised: 08/12/2004] [Accepted: 08/14/2004] [Indexed: 11/28/2022]
Abstract
Joining aryl 8-azabicyclo[3.2.1]oct-3-enes with aryloxyethanes and aryloxypropanes produces novel series of compounds 11 and 12 with potent 5-HT-T affinity and moderately potent 5-HT(1A) affinity. Moreover, several of these compounds possess functional 5-HT(1A) antagonism. Optimal compounds are, 4-indolyloxyethane 21, 4-indolyloxypropanes 25, and 27, which possess potent 5-HT-T affinity (5-HT-T K(i): 21: 1.2nM, 25: 0.54nM, 27: 0.38nM) and good 5-HT(1A) affinity/antagonism (5-HT(1A)K(i), [(35)S]GTPgammaS: E(max) (%): 21: 111.1nM, 0%; 25: 173.2nM, 0%; 27: 107nM, 0%).
Collapse
Affiliation(s)
- Adam M Gilbert
- Chemical and Screening Sciences, Wyeth Research, 401 N. Middletown Road, Pearl River, NY 10965-1215, USA.
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, Artigas F. Strategies for producing faster acting antidepressants. Drug Discov Today 2005; 10:578-85. [PMID: 15837601 DOI: 10.1016/s1359-6446(05)03398-2] [Citation(s) in RCA: 102] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Existing antidepressant treatments exhibit limited efficacy and a slow onset of action. Several neurobiological adaptive mechanisms might delay the clinical effects of antidepressants, whose therapeutic action is primarily triggered by an increase of serotonergic and noradrenergic neurotransmission. Here, we review several potential mechanisms that could be useful to increase the speed of current antidepressant drugs, such as additional blockade of aminergic autoreceptors or antagonism of certain postsynaptic (5-HT2A, 5-HT2C) receptors. The potential use of strategies not based on monoaminergic transmission, such as CRF and NK1 receptor antagonists, or more novel strategies, based on glutamatergic or GABAergic transmission or on intracellular messengers, are also reviewed.
Collapse
Affiliation(s)
- Albert Adell
- Department of Neurochemistry, Institut d' Investigacions Biomèdiques de Barcelona (CSIC), IDIBAPS, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
46
|
Schmitz WD, Denhart DJ, Brenner AB, Ditta JL, Mattson RJ, Mattson GK, Molski TF, Macor JE. Homotryptamines as potent and selective serotonin reuptake inhibitors (SSRIs). Bioorg Med Chem Lett 2005; 15:1619-21. [PMID: 15745809 DOI: 10.1016/j.bmcl.2005.01.059] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2005] [Revised: 01/24/2005] [Accepted: 01/25/2005] [Indexed: 11/17/2022]
Abstract
A series of N,N-dimethylhomotryptamines was prepared and their binding affinities at the serotonin transporter (SERT) were determined. Compounds possessing an electron withdrawing substituent at the C5-position of the indole nucleus were found to be potent SSRIs. Initial attempts at conformational restriction of the propylamine sidechain by incorporation of a quinuclidine bicyclic structure did not improve binding affinity at SERT.
Collapse
Affiliation(s)
- William D Schmitz
- Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492-7660, USA.
| | | | | | | | | | | | | | | |
Collapse
|